152 related articles for article (PubMed ID: 36867850)
41. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
42. What is new in acute myeloid leukemia classification?
Park HS
Blood Res; 2024 Apr; 59(1):15. PubMed ID: 38616211
[TBL] [Abstract][Full Text] [Related]
43. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
44. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
45. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
46. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
47. Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center.
Narayanan S
J Blood Med; 2017; 8():21-27. PubMed ID: 28260960
[TBL] [Abstract][Full Text] [Related]
48. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Shallis RM; Daver NG; Altman JK; Hasserjian RP; Kantarjian HM; Platzbecker U; Santini V; Wei AH; Sallman DA; Zeidan AM
Cancer; 2023 Jan; 129(2):175-180. PubMed ID: 36397669
[TBL] [Abstract][Full Text] [Related]
49. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
50. Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review.
Guo ZP; Tan YH; Li JL; Xu ZF; Chen XH; Xu LR
Oncol Lett; 2018 Jun; 15(6):9745-9750. PubMed ID: 29805685
[TBL] [Abstract][Full Text] [Related]
51. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
[TBL] [Abstract][Full Text] [Related]
52. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
53. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
54. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
55. [Diagnosis and treatment of childhood myelodysplastic syndrome].
Hasegawa D
Rinsho Ketsueki; 2021; 62(4):229-238. PubMed ID: 33967145
[TBL] [Abstract][Full Text] [Related]
56. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
57. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
59. Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine.
Sato K; Tsukada N; Inamura J; Komatsu S; Sato K; Yamamoto M; Shindo M; Moriichi K; Mizukami Y; Fujiya M; Torimoto Y; Okumura T
Case Rep Hematol; 2021; 2021():6640597. PubMed ID: 33976945
[TBL] [Abstract][Full Text] [Related]
60. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
